Tumor necrosis factor alpha (TNF-α) has a broad spectrum of biological activities. In addition to its central role in inflammation TNF-α is involved in regulating apoptotic cell death, cellular proliferation, and differentiation.
MACS GMP Recombinant Human TNF-α is designed for ex vivo cell culture processing. No animal- or human-derived materials were used for the manufacture of this product, unless otherwise stated in the respective Certificate of Origin. The product is lyophilized without carrier protein or preservatives.
Related products for MACS® GMP Recombinant Human TNF-α
Tumor necrosis factor alpha (TNF-α) has a broad spectrum of biological activities. In addition to its central role in inflammation TNF-α is involved in regulating apoptotic cell death, cellular proliferation, and differentiation.
MACS GMP Recombinant Human TNF-α is designed for ex vivo cell culture processing. No animal- or human-derived materials were used for the manufacture of this product, unless otherwise stated in the respective Certificate of Origin. The product is lyophilized without carrier protein or preservatives.
TNFSF2
Biological activity
TNF-α is mainly produced by activated monocytes and macrophages, but also by a broad variety of other cell types including lymphoid cells, mast cells, endothelial cells, fibroblasts, and astrocytes. Beside its primary role in immune regulation, TNF-α promotes angiogenesis, bone resorption, and thrombotic processes.
MACS GMP Recombinant Human TNF-α can be used for a variety of applications, including the ex vivo generation of human dendritic cells from enriched CD14+ monocyte populations.2–4
Technical specifications
- Identity/ Molecular mass: 17353 Da, determined by mass spectrometry. This corresponds to the mature form of human TNF-α (157 amino acids).
- Purity: ≥ 95 % as determined by chip electrophoresis.
- Endotoxin content: < 50 EU/mg, as determined by kinetic Limulus Amoebocyte Lysate (LAL) assay (Pharmacopoeia Europaea (Ph. Eur.)).
- Residual host cell DNA content: < 50 ng/mg, as determined by quantitative PCR specific for E. coli genomic DNA.
- Residual host cell protein content: < 0.5 µg/mg, as determined by E. coli HCP ELISA.
- Identity/ Molecular mass: 17353 Da, determined by mass spectrometry. This corresponds to the mature form of human TNF-α (157 amino acids).
- Purity: ≥ 95 % as determined by chip electrophoresis.
- Endotoxin content: < 50 EU/mg, as determined by kinetic Limulus Amoebocyte Lysate (LAL) assay (Pharmacopoeia Europaea (Ph. Eur.)).
- Residual host cell DNA content: < 50 ng/mg, as determined by quantitative PCR specific for E. coli genomic DNA.
- Residual host cell protein content: < 0.5 µg/mg, as determined by E. coli HCP ELISA.
The product quality certificate of our MACS® GMP Recombinant Human IL-TNF-α was adapted. Learn more here
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
Mass spectrometry analysis (ESI-MS) of MACS GMP Recombinant Human TNF-α. The peak corresponds to the calculated molecular mass of 17353 Da.
MACS GMP Recombinant Human TNF-α biological activity. Activity of Human TNF-α, GMP grade, (blue bar) was compared to other commercially available products (black and grey bar).
MACS GMP Recombinant Human TNF-α batch-to-batch variability. Activity of three different production batches of Human MACS GMP TNF-α.
Enter the lot number from your product label to access its Product Quality Certificated (PQC).
- Baarsch, M. J. et al. (1991) Detection of tumor necrosis factor alpha from porcine alveolar macrophages using an L929 fibroblast bioassay. J. Immunol. Methods 140: 15-22
- Bender, A. et al. (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196: 121-135
- Romani, N. et al. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196: 137-151
- Jonuleit, H. et al. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27: 3135-3142
You have previously chosen International as your location.
What do you want to do?